Shots:
- Evoq to receive ~$240M up front & milestones along with royalties on the sales of therapies emerges from the collaboration
- The companies collaborated on preclinical development, while Amgen will be responsible for clinical development and commercialization
- The collaboration will bolster Amgen’s autoimmune offerings as its portfolio contains innovative medicines, including Otezla and Enbrel, and biosimilar products, such as Amgevita (a biosimilar to Humira) and Avsola (a biosimilar to Remicade)
Click here to read full press release/ article | Ref: PRNewswire | Image: Stat
The post Amgen Collaborates with Evoq to Develop Novel Therapies for Autoimmune Disorders first appeared on PharmaShots.
